Results 131 to 140 of about 117,248 (268)

Outpatients' cardiac rehabilitation: the long-term experience of the Niguarda Hospital. [PDF]

Int J Cardiol Cardiovasc Risk Prev
Fortuna M, Tognola C, Luongo A, Biolcati M, Alloni M, Prencipe GP, Invernici B, D'Alesio S, Venturelli F, Steccanella F, Tateo V, Pedretti MC, Zadra L, Riccobono S, Giannattasio C, Maloberti A.   +15 more
europepmc   +1 more source

Efficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo‐Controlled Phase 3 Trials

Arthritis &Rheumatology, EarlyView.
Objective DISSOLVE I and II examined the efficacy and safety of nanoencapsulated sirolimus (NAS) plus pegadricase (NASP) in patients with uncontrolled gout (UG). Methods In these double‐blind, placebo‐controlled Phase 3 trials of NASP, patients were randomized 1:1:1 to infusions of high‐dose (HD) or low‐dose (LD) NAS plus pegadricase (HD NASP, LD NASP,
Herbert S. B. Baraf, Puja P. Khanna, Milan Petronijevic, Mamuka Lortkipanidze, Anand Patel, Kwabena Ayesu, Michael H. Pillinger, Atul Singhal, Joanna Sobierska, Jacquie Christie, Peter Traber, Rehan Azeem, Wesley DeHaan, Hugues Santin‐Janin, Bhavisha Desai, Alan Kivitz   +15 more
wiley   +1 more source

Pharmacokinetics, Effectiveness and Safety of Certolizumab Pegol in Children and Adolescents With Active Juvenile Idiopathic Arthritis: 9+‐Year Results From a Multicenter, Open‐Label Study

Arthritis &Rheumatology, EarlyView.
Objective The purpose of this study was to assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods Pediatric Arthritis Study of Certolizumab Pegol (NCT01550003), a multicenter, open‐label study, enrolled patients aged 2 to 17 years with ...
Hermine I. Brunner, Lyudmila Grebenkina, Irina Nikishina, Ekaterina Alexeeva, Vyacheslav Chasnyk, Carlos Abud‐Mendoza, Nadina Rubio‐Pérez, Heinrike Schmeling, María del Rocio Maldonado‐Velázquez, Diane Brown, Andrew Zeft, Esi Morgan, C. Egla Rabinovich, Daniel Kingsbury, Hulya Bukulmez, Beth Gottlieb, Thomas Griffin, Lisa Imundo, Stacey Tarvin, Earl Silverman, Laura Shaughnessy, Saori Shimizu, Paulette Williams, Rocío Lledó‐García, Gauri Utturkar, Baran Ufuktepe, Alberto Martini, Daniel J. Lovell, Nicolino Ruperto, the Paediatric Rheumatology International Trials Organisation (PRINTO); the Pediatric Rheumatology Collaborative Study Group (PRCSG), Hermine I. Brunner, Lyudmila Grebenkina, Irina Nikishina, Ekaterina Alexeeva, Vyacheslav Chasnyk, Carlos Abud‐Mendoza, Nadina Rubio‐Pérez, Heinrike Schmeling, María del Rocio Maldonado‐Velázquez, Diane Brown, Andrew Zeft, Esi Morgan, C. Egla Rabinovich, Daniel Kingsbury, Hulya Bukulmez, Beth Gottlieb, Thomas Griffin, Lisa Imundo, Stacey Tarvin, Earl Silverman, Alberto Martini, Daniel L. Lovell, Nicolino Ruperto   +52 more
wiley   +1 more source

Association Between Registered Instructors of Cardiac Rehabilitation and Inpatient Cardiac Rehabilitation Participation in Japan: A Nationwide 10-Year Analysis. [PDF]

Circ Rep
Sawamura A, Kanaoka K, Katano S, Kono Y, Motokawa T, Ohya Y, Miura SI, Fukuma N, Makita S, Miyamoto Y, Fukumoto Y, Izawa H.   +11 more
europepmc   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, EarlyView.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source

Cancer in Systemic Sclerosis: Clinical Associations and Prognostic Impact From the EUSTAR Registry

Arthritis &Rheumatology, EarlyView.
Objective Cancer represents a major cause of death in systemic sclerosis (SSc). Established risk factors are limited to specific subsets, particularly early diffuse anti‐RNA polymerase III (POLR3)–positive disease, needing further exploration. Methods We performed a nested case‐control study within the European Scleroderma Trials and Research group ...
Antonio Tonutti, Francesca Motta, Liala Moschetti, Cosimo Bruni, Carina Mihai, Claudia Iannone, Maria Rosa Pellico, Stefano Stano, Stefano Erba, Claudia Barison, Eleonora Pazzi, Andrea Benini, Beatrice Moccaldi, Kurszán Jász Dávid, Ágnes Ágoston‐Szabó, Beatrice Gabrielli, Francesca Nava, Dóra Tari, Francesca Romana Di Ciommo, Yuri Sasaki, Gonçalo Boleto, Radim Bečvář, Alejandro Brigante, Britta Maurer, Massimiliano Limonta, Rahma A. Elziaty, Fabiola Atzeni, Lilian Maria López Núñez, Roberta Foti, Francesco Benvenuti, Brigitte Granel, Elena Rezus, Leila Caillault, Sophie Blaise, Cristiana Sieiro Santos, Fabio Cacciapaglia, Roberto Giacomelli, Rossella De Angelis, Serena Guiducci, Duygu Temiz Karadag, Gabriella Szűcs, Luca Idolazzi, Gábor Kumánovics, Florenzo Iannone, Maurizio Cutolo, Gianluca Moroncini, Valeria Riccieri, Nicoletta Del Papa, Elisabetta Zanatta, Oliver Distler, Masataka Kuwana, Carlo Selmi, Maria De Santis   +52 more
wiley   +1 more source

Cardiac Rehabilitation in Heart Failure: Evidence, Coverage, and Implementation. [PDF]

J Clin Med
Aggarwal P, Yannamani A, Jain J, Klipa I, Oehler A, Kassis-George H.   +5 more
europepmc   +1 more source

AMETHYST: A Retrospective Cohort Study of Treatment Patterns and Outcomes in Patients With Glucocorticoid‐Refractory Macrophage Activation Syndrome Complicating Still's Disease

Arthritis &Rheumatology, EarlyView.
Objective Information is limited on the natural history and current treatment patterns in macrophage activation syndrome (MAS), a life‐threatening hyperinflammatory syndrome complicating Still's disease (systemic juvenile idiopathic arthritis [sJIA] and adult‐onset Still's disease [AOSD]).
Alexei Grom, Jordi Antón, Edward M. Behrens, Corey Best, Norbert Blank, Josefin Blomkvist, Scott W. Canna, Sonia Carriquí, Shanmuganathan Chandrakasan, Andrew Danquah, Ngoc‐Bao Duong, Brian D. Jamieson, Paivi Miettunen, Abiola Oladapo, Sampath Prahalad, Pierre Quartier, Grant Schulert, Anna Stoltenberg, Uwe Ullmann, Erika Van Nieuwenhove, Sebastiaan J. Vastert, Fabrizio De Benedetti   +21 more
wiley   +1 more source

Expert Perspectives: Toward Treat‐to‐Target Management in Adult Idiopathic Inflammatory Myopathies

Arthritis &Rheumatology, EarlyView.
Treat‐to‐target has transformed the management of several rheumatic diseases through predefined therapeutic goals, structured disease assessment, and timely treatment adjustment. Despite major advances in the understanding and treatment of idiopathic inflammatory myopathies (IIM), a formal treat‐to‐target framework for adult IIM has not yet been ...
Shiri Keret, Nantakarn Pongtarakulpanit, Rohit Aggarwal   +2 more
wiley   +1 more source

Military Cardiac Rehabilitation [PDF]

Journal of the Royal Army Medical Corps, 1992
openaire   +2 more sources